Lithium, Nortriptyline, and Phenelzine

The combination of lithium, nortriptyline, and phenelzine appears to be a treatment approach used in psychiatry, particularly for treatment-resistant depression. This combination brings together three different classes of psychiatric medications: a mood stabilizer (lithium), a tricyclic antidepressant (nortriptyline), and a monoamine oxidase inhibitor (phenelzine). ## Mechanism and Clinical Use This combination therapy represents an aggressive pharmacological approach for patients with severe, treatment-resistant depression. Each component has a distinct mechanism of action: - **Phenelzine** is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) that works by increasing levels of dopamine, norepinephrine, and serotonin in the brain to help regulate mood[6][10]. It's typically used for atypical, nonendogenous, or neurotic depression when other treatments have failed[5][8]. - **Lithium** functions as a mood stabilizer and is often used as an augmentation strategy in patients who have failed to respond to antidepressant monotherapy[1]. It has been studied specifically in combination with MAOIs like phenelzine, showing efficacy in severely depressed patients who had previously failed to respond to tricyclic antidepressants[2]. - **Nortriptyline** is a tricyclic antidepressant that primarily affects noradrenergic neurotransmission. The combination of nortriptyline with MAOIs like phenelzine has been documented in case studies, with some patients remaining stable on this combination for extended periods[3]. ## Safety Considerations This combination requires careful medical supervision due to potential serious interactions: 1. The combination of lithium with an MAOI like phenelzine has been studied in treatment-resistant depression, but requires careful monitoring for side effects[2][4]. 2. Nortriptyline should not be used with MAOIs without careful medical supervision due to the risk of serotonin syndrome, a potentially life-threatening condition[9]. 3. Elderly patients may be particularly susceptible to side effects from these medications, especially neuromuscular or neurologic symptoms[1]. 4. The triple combination would require extremely careful dosing and monitoring for drug interactions and side effects. ## Clinical Evidence There is limited published evidence specifically on the triple combination of lithium, nortriptyline, and phenelzine. However, the search results do reference: - A case study (patient #12) mentioning a 57-year-old woman with recurrent major depressive disorder who was treated with phenelzine 60 mg, nortriptyline 150 mg, and lithium (among other medications) for approximately 2 years, with the patient successfully remaining on this combination therapy without relapse or significant adverse effects[3]. - Studies on lithium augmentation of MAOIs like phenelzine for treatment-resistant depression[2][4]. - Research on the combination of MAOIs with tricyclic antidepressants like nortriptyline, with some patients remaining stable on this combination for extended periods[3]. This triple combination would likely only be considered in cases of severe, treatment-resistant depression where multiple other treatment approaches have failed, and would require close monitoring by a psychiatrist experienced in managing complex psychopharmacology.